GSK PLC-SPON ADR (GSK) Stock Institutional Trading Activity


GSK PLC-SPON ADR (GSK) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Causeway Capital Management, Renaissance Technologies LLC, Kahn Brothers Group, Hancock Classic Value, and Dodge & Cox Stock Fund. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q3 2023Hillman Value FundSell-1,817232,864$8,441,320
Q3 2023Causeway Capital ManagementBuy165,317564,747$20,472,082
Q3 2023Dodge & Cox Stock FundSell-330,08569,281,183$2,511,442,884
Q3 2023Tweedy, Browne Co All Funds (US)Sell-4,520129,994$4,712,282
Q2 2023Renaissance Technologies LLCSell-1,207,3173,022,134$107,709
Q2 2023Sequoia Financial AdvisorsBuy36314,107$502,774
Q2 2023Ariel Appreciation FundSell-13,691171,677$6,118,568
Q2 2023Hillman Value FundSell-2,735234,681$8,364,031
Q2 2023Causeway Capital ManagementBuy80,270399,430$14,235,678
Q2 2023Dodge & Cox Stock FundSell-95,80069,611,268$2,480,945,592
Q2 2023Tweedy, Browne Co All Funds (US)Sell-861134,514$4,794
Q1 2023First Eagle U.S. ValueSell-59,4573$101
Q1 2023Renaissance Technologies LLCSell-2,107,7004,229,451$150,484
Q1 2023Sequoia Financial AdvisorsBuy2,82413,744$489,012
Q1 2023Ariel Appreciation FundBuy80185,368$6,595,393
Q1 2023Hillman Value FundSell-463237,416$8,447,261
Q1 2023Causeway Capital ManagementBuy82,127319,160$11,355,718
Q1 2023Dodge & Cox Stock FundBuy4,774,11669,707,068$2,480,177,479
Q1 2023Tweedy, Browne Co All Funds (US)Sell-3,952135,375$4,817
Q4 2022Renaissance Technologies LLCSell-3,016,9066,337,151$222,687
Q4 2022Sequoia Financial AdvisorsBuy10,92010,920$383,729
Q4 2022First Eagle U.S. ValueBuy9,90159,460$2,089,410
Q4 2022Ariel Appreciation FundBuy15,727185,288$6,511,020
Q4 2022Causeway Capital ManagementBuy53,489237,033$8,329,323
Q4 2022Hillman Value FundSell-6,099237,879$8,359,068
Q4 2022Dodge & Cox Stock FundBuy6,348,96364,932,952$2,281,743,933
Q4 2022Tweedy, Browne Co All Funds (US)Buy139,327139,327$4,896
Q3 2022First Eagle U.S. ValueBuy49,55949,559$1,459
Q3 2022Ariel Appreciation FundBuy169,561169,561$4,990
Q3 2022Causeway Capital ManagementSell-74,619183,544$5,402

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.